Remed Co.,Ltd.
Financials
Valuation Metrics
Remed Co.,Ltd.'s Market Cap is ₩875B. At end of 2025 it was ₩949B. Ranked #1324 of 2,436 in KR market (top 54%), #728 of 1,649 on KOSDAQ (top 44%), #52 of 96 in Health Care Equipment & Services (top 54%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 87.47B KRW | KR#1,324/2,436 Sec#52/96 |
| Revenue | 25.24B KRW | KR#2,082/2,436 Sec#70/96 |
| Net Income | 764.1M KRW | KR#1,444/2,436 Sec#47/96 |
| Total Assets | 54.74B KRW | KR#2,146/2,436 Sec#71/96 |
| Net Assets | 39.24B KRW | KR#2,032/2,436 Sec#72/96 |
| Employees | 104 | KR#1,600/2,436 Sec#55/96 |
| Value | ||
| P/E | 114.48x | KR#1,449/2,436 Sec#47/96 |
| P/B | 2.23x | KR#1,994/2,436 Sec#70/96 |
| PEG | 0.31x | KR#600/2,436 Sec#24/96 |
| P/S | 3.47x | KR#2,048/2,436 Sec#67/96 |
| EV/EBITDA | 75.99x | KR#1,431/2,436 Sec#45/96 |
| Profitability | ||
| ROE | 1.95% | KR#1,330/2,436 Sec#46/96 |
| ROA | 1.40% | KR#1,244/2,436 Sec#45/96 |
| Op. Margin | 4.09% | KR#1,039/2,436 Sec#45/96 |
| Revenue Growth | 11.37% | KR#871/2,436 Sec#41/96 |
| Earnings Growth | 366.39% | KR#148/2,436 Sec#5/96 |
| Financial Health | ||
| Debt Ratio | 139.51% | KR#1,024/2,436 Sec#52/96 |
| Total Debt | 1.12B KRW | KR#1,949/2,436 Sec#73/96 |
| Cash | 10.12B KRW | KR#1,664/2,436 Sec#59/96 |
| Current Ratio | 2.75x | KR#676/2,436 Sec#39/96 |
| Net Debt/EBITDA | -8.72x | KR#74/2,436 Sec#5/96 |
| Performance | ||
| 1Y Return | -15.27% | KR#1,113/2,436 Sec#31/96 |
| 1M Return | 3.66% | KR#561/2,436 Sec#28/96 |
| From 52W High | -38.41% | KR#689/2,436 Sec#24/96 |
| 1Y MDD | -37.64% | KR#436/2,436 Sec#11/96 |
| Trading | ||
| Volume | 136,379 shares | KR#767/2,436 Sec#31/96 |
| Foreign Own. | 0.48% | KR—/2,436 Sec—/96 |
| Per Share | ||
| EPS | 38 KRW | KR#1,464/2,436 Sec#48/96 |
| BPS | 1,309 KRW | KR#2,210/2,436 Sec#81/96 |
Company Info
REMED, established in 2003 and headquartered in Cheongju-si, Chungcheongbuk-do, develops and manufactures non-invasive medical devices that induce nerve cell depolarization using strong magnetic fields. The company operates in brain rehabilitation, chronic pain treatment, and aesthetics, with its neuromodulation device for chronic pain treatment and transcranial magnetic stimulation device for brain rehabilitation having received U.S. FDA approval in 2021. REMED is targeting the global market by entering the U.S. market for TMS for depression treatment, expanding sales internationally, conducting clinical trials for mental illnesses, and premiumizing Peripheral Magnetic Stimulation products.